How Genetesis CEO Peeyush Shrivastava grew to $4.8M revenue with a 41 person team in 2023.

Genetesis is a commercial-stage medical technology company revolutionizing the diagnosis and triage of myocardial ischemia and coronary artery disease. Leveraging noninvasive biomagnetic imaging technology, proprietary cloud-based web services, and advanced machine-learning capabilities, Genetesis aims to redefine clinical diagnostic processes. The company's initial focus is on establishing itself as the ultimate rule-out test for clinically significant myocardial ischemia in acute care settings. This approach is designed to complement the use of the 12-lead EKG and serial troponin tests.

To achieve its objectives, Genetesis has developed a unique web microservices architecture known as the Faraday Analytical Cloud. This platform integrates the CardioFlux FAC Magnetocardiograph, an easy-to-operate, noninvasive biomagnetic imaging device, with sophisticated proprietary algorithms. These algorithms analyze magnetic field maps generated by the device, converting complex data into clinically relevant information. This information is seamlessly integrated into clinical and revenue cycle management workflows, enhancing both patient care and operational efficiency.

The CardioFlux FAC Magnetocardiograph represents a significant advancement in medical imaging, offering a highly available solution for the detection and management of cardiac conditions. By combining cutting-edge technology with a focus on accessibility and ease of use, Genetesis is poised to make a lasting impact on the field of cardiology and the broader healthcare industry.